Literature DB >> 33441326

Translation initiation in cancer at a glance.

Rachael C L Smith1,2, Georgios Kanellos1, Nikola Vlahov1, Constantinos Alexandrou1, Anne E Willis3, John R P Knight4, Owen J Sansom1,2.   

Abstract

Cell division, differentiation and function are largely dependent on accurate proteome composition and regulated gene expression. To control this, protein synthesis is an intricate process governed by upstream signalling pathways. Eukaryotic translation is a multistep process and can be separated into four distinct phases: initiation, elongation, termination and recycling of ribosomal subunits. Translation initiation, the focus of this article, is highly regulated to control the activity and/or function of eukaryotic initiation factors (eIFs) and permit recruitment of mRNAs to the ribosomes. In this Cell Science at a Glance and accompanying poster, we outline the mechanisms by which tumour cells alter the process of translation initiation and discuss how this benefits tumour formation, proliferation and metastasis.
© 2021. Published by The Company of Biologists Ltd.

Entities:  

Keywords:  Cancer; Cell signalling; Translation

Mesh:

Substances:

Year:  2021        PMID: 33441326     DOI: 10.1242/jcs.248476

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  7 in total

1.  eIF6 as a Promising Diagnostic and Prognostic Biomarker for Poorer Survival of Cutaneous Melanoma.

Authors:  Fangyingnan Zhang; Saquib Waheed; Ubaldo Armato; Jun Wu; Chao Zhang; Zhibin Li
Journal:  Front Oncol       Date:  2022-05-30       Impact factor: 5.738

2.  Tuning protein synthesis for cancer therapy.

Authors:  John R P Knight; Owen J Sansom
Journal:  Mol Cell Oncol       Date:  2021-02-22

3.  Rpl24Bst mutation suppresses colorectal cancer by promoting eEF2 phosphorylation via eEF2K.

Authors:  John Rp Knight; Nikola Vlahov; David M Gay; Rachel A Ridgway; William James Faller; Christopher Proud; Giovanna R Mallucci; Tobias von der Haar; Christopher Mark Smales; Anne E Willis; Owen J Sansom
Journal:  Elife       Date:  2021-12-13       Impact factor: 8.140

Review 4.  Targeting Ribosome Biogenesis to Combat Tamoxifen Resistance in ER+ve Breast Cancer.

Authors:  Ho Tsoi; Chan-Ping You; Man-Hong Leung; Ellen P S Man; Ui-Soon Khoo
Journal:  Cancers (Basel)       Date:  2022-02-28       Impact factor: 6.639

5.  The context of the ribosome binding site in mRNAs defines specificity of action of kasugamycin, an inhibitor of translation initiation.

Authors:  Yan Zhang; Nikolay A Aleksashin; Dorota Klepacki; Caleb Anderson; Nora Vázquez-Laslop; Carol A Gross; Alexander S Mankin
Journal:  Proc Natl Acad Sci U S A       Date:  2022-01-25       Impact factor: 11.205

Review 6.  Circular RNAs' cap-independent translation protein and its roles in carcinomas.

Authors:  Lian He; Changfeng Man; Shouyan Xiang; Lin Yao; Xiaoyan Wang; Yu Fan
Journal:  Mol Cancer       Date:  2021-09-15       Impact factor: 27.401

Review 7.  The Cap-Binding Complex CBC and the Eukaryotic Translation Factor eIF4E: Co-Conspirators in Cap-Dependent RNA Maturation and Translation.

Authors:  Jean-Clement Mars; Mehdi Ghram; Biljana Culjkovic-Kraljacic; Katherine L B Borden
Journal:  Cancers (Basel)       Date:  2021-12-08       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.